Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: A meta‐analysis. Issue 12 (22nd November 2021)

• Record Type: Journal Article
• Authors: Yang, Di‐Xiao; Li, Yao; Yu, Dan; Guan, Bi; Ming, Qian; Li, Yan; Chen, Li‐Qing
• Is Part Of: Brain and behavior. Volume 11:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-11-22
• Subjects: acute ischemic stroke -- edaravone -- human urinary kallidinogenase -- meta‐analysis; Neurology -- Periodicals; Neurosciences -- Periodicals; Psychology -- Periodicals; Psychiatry -- Periodicals; 616.8005
• DOI: 10.1002/brb3.2431
• Languages: English
• ISSNs: 2162-3279

Abstract

Abstract: Introduction: Several studies have investigated the efficacy of human urinary kallidinogenase (HUK) combined with edaravone (Eda) in acute ischemic stroke (AIS) patients. Our aim was to provide the best available evidence for clinical practice and further research programs for stroke treatment. Methods: We searched the online database for paper published between January 2015 and April 2021. We calculated weighted mean difference (WMD) or odds risk (OR) and their corresponding 95% confidence interval (95% CI) of reported outcomes between HUK plus Eda and Eda groups for each study. The random‐effect models or fixed‐effect models were used to pool the analysis. Results: Thirteen studies with 1242 patients were included. In the pooled analysis, the scores of NIHSS in the HUK plus Eda group were significantly lower than that in patients receiving Eda (WMD = –3.92, 95% CI (–4.82, –3.02), p < .0001). The ADL scores in the HUK plus Eda group were significantly greater than that in patients receiving Eda (WMD = 14.13, 95% CI (10.67, 17.60), p < .0001). Furthermore, HUK plus Eda was associated with a higher rate of total efficacy (OR = 3.97, 95% CI (2.81, 5.59), p < .0001). Conclusions: HUK combined with Eda provides potential clinical benefits as a treatment for AIS. Further high‐quality, large‐scale randomized trials are needed to confirm these results. Abstract : Our results provided further evidence that HUK combined with Eda provides potential clinical benefits as a treatment for AIS.